Sagimet Biosciences
Sagimet Biosciences is a clinical‑stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic and fibrotic pathways. Its lead product candidate, denifanstat, is an oral, once‑daily selective FASN inhibitor intended for conditions such as acne, metabolic dysfunction‑associated steatohepatitis (MASH), and certain FASN‑dependent solid tumors. The company has received IND clearance and plans to advance denifanstat into a registrational Phase 3 trial in moderate to severe acne patients in the second half of 2026.
Sagimet Biosciences is profiled on the APIs.io network. Tagged areas include Fatty Acid Synthase Inhibitors, Dermatology, Metabolic Disease, and Oncology.
Kin Score
Terms of Service 1
What its API terms permit and prohibit, quoted from its own page.
Sagimet Biosciences
10 quoted statements, read from Sagimet Biosciences's own page on 2026-11-10.
TERMSPrivacy & Data 1
Its role, the data it processes, retention and transfers, quoted from its own privacy page.
Sagimet Biosciences
7 quoted statements, read from Sagimet Biosciences's own page on 2026-11-10.
PRIVACYEligibility 1
Who may sign up and where, quoted from its own terms.
Sagimet Biosciences
2 quoted statements, read from Sagimet Biosciences's own page on 2026-11-10.
ELIGIBILITYData License 1
How its data and outputs may be reused, quoted from its own terms.
Sagimet Biosciences
2 quoted statements, read from Sagimet Biosciences's own page on 2026-11-10.
LICENSESecurity Posture 1
Authentication, domain security, vulnerability disclosure, and trust-center signals.
Resources
Access & Security 1
Authentication, authorization, and security posture
Commercial 4
Pricing, plans, and the legal terms of use
Company 1
The organization behind the API
Other 3
Properties that don't map to a standard resource type
Source (apis.yml)
Work with this as data
Every provider here is available over the APIs.io API and to AI agents over MCP.